Relief Therapeutics Holding AG (RLFTY)
USD 3.0
(-16.43%)
USD 3.0
(-16.43%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -110.82 Million CHF | 61.75% |
| 2022 | -52.04 Million CHF | -51.69% |
| 2021 | -34.3 Million CHF | -277.61% |
| 2020 | -9.08 Million CHF | 24.68% |
| 2019 | -12.06 Million CHF | -2512.4% |
| 2018 | 500 Thousand CHF | 128.8% |
| 2017 | -1.73 Million CHF | 89.47% |
| 2016 | -16.48 Million CHF | -331.75% |
| 2015 | -3.81 Million CHF | 68.45% |
| 2014 | -12.1 Million CHF | -5.5% |
| 2013 | -11.47 Million CHF | -85.66% |
| 2012 | -6.17 Million CHF | 89.56% |
| 2011 | -59.16 Million CHF | -207.39% |
| 2010 | -19.24 Million CHF | -58.97% |
| 2009 | -12.1 Million CHF | -32.05% |
| 2008 | -9.16 Million CHF | -428.68% |
| 2007 | -1.73 Million CHF | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -1.98 Million CHF | 75.91% |
| 2024 Q2 | -1.98 Million CHF | 0.0% |
| 2023 Q4 | -8.25 Million CHF | -100.34% |
| 2023 Q2 | -11.64 Million CHF | -100.86% |
| 2023 Q1 | -5.79 Million CHF | 62.78% |
| 2023 Q3 | -4.12 Million CHF | 64.61% |
| 2023 FY | -19.9 Million CHF | 61.75% |
| 2022 Q3 | -7.35 Million CHF | 64.91% |
| 2022 Q4 | -15.57 Million CHF | -111.73% |
| 2022 FY | -52.04 Million CHF | -51.69% |
| 2022 Q1 | -10.12 Million CHF | 42.94% |
| 2022 Q2 | -20.96 Million CHF | -107.14% |
| 2021 Q3 | -9.44 Million CHF | 36.85% |
| 2021 Q2 | -14.95 Million CHF | -94.74% |
| 2021 FY | -34.3 Million CHF | -277.61% |
| 2021 Q4 | -17.73 Million CHF | -87.89% |
| 2021 Q1 | -7.67 Million CHF | 51.39% |
| 2020 Q1 | -1.75 Million CHF | -233.17% |
| 2020 Q3 | -7.92 Million CHF | -126.22% |
| 2020 Q4 | -15.79 Million CHF | -99.18% |
| 2020 FY | -9.08 Million CHF | 24.68% |
| 2020 Q2 | -3.5 Million CHF | -100.0% |
| 2019 Q4 | -526 Thousand CHF | -100.0% |
| 2019 FY | -12.06 Million CHF | -2512.4% |
| 2019 Q2 | -421 Thousand CHF | -100.0% |
| 2019 Q1 | -210.5 Thousand CHF | -439.74% |
| 2019 Q3 | -263 Thousand CHF | 37.53% |
| 2018 Q4 | -39 Thousand CHF | 0.0% |
| 2018 FY | 500 Thousand CHF | 128.8% |
| 2018 Q1 | -211 Thousand CHF | 38.48% |
| 2018 Q2 | -211 Thousand CHF | 0.0% |
| 2018 Q3 | -39 Thousand CHF | 81.52% |
| 2017 Q2 | -525 Thousand CHF | 0.0% |
| 2017 Q1 | -525 Thousand CHF | 36.82% |
| 2017 Q3 | -343 Thousand CHF | 34.67% |
| 2017 Q4 | -343 Thousand CHF | 0.0% |
| 2017 FY | -1.73 Million CHF | 89.47% |
| 2016 Q3 | -831 Thousand CHF | -513.28% |
| 2016 FY | -16.48 Million CHF | -331.75% |
| 2016 Q1 | -135.5 Thousand CHF | 0.0% |
| 2016 Q2 | -135.5 Thousand CHF | 0.0% |
| 2016 Q4 | -831 Thousand CHF | 0.0% |
| 2015 FY | -3.81 Million CHF | 68.45% |
| 2014 FY | -12.1 Million CHF | -5.5% |
| 2013 FY | -11.47 Million CHF | -85.66% |
| 2012 FY | -6.17 Million CHF | 89.56% |
| 2011 FY | -59.16 Million CHF | -207.39% |
| 2010 FY | -19.24 Million CHF | -58.97% |
| 2009 FY | -12.1 Million CHF | -32.05% |
| 2008 FY | -9.16 Million CHF | -428.68% |
| 2007 FY | -1.73 Million CHF | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -8199.044% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 235.401% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -28348.803% |
| Nascent Biotech, Inc. | -2.22 Million USD | -4870.135% |
| Qrons Inc. | -643.67 Thousand USD | -17117.952% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -16033.343% |
| Evofem Biosciences, Inc. | -17.84 Million USD | -520.99% |
| BioStem Technologies, Inc. | -7.77 Million USD | -1324.713% |
| Skye Bioscience, Inc. | -13.67 Million USD | -710.632% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -26574.754% |
| Rebus Holdings, Inc. | -664 Thousand USD | -16590.964% |
| CSL Limited | 3.7 Billion USD | 102.994% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | -99.661% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -8723.885% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -598.361% |
| Adynxx, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -2097.014% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | -54.387% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 2354.98% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -42245.048% |
| SQZ Biotechnologies Company | -75.82 Million USD | -46.163% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -3788.01% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -7115.134% |
| Mesoblast Limited | -84.14 Million USD | -31.708% |
| Marizyme, Inc. | -34.08 Million USD | -225.137% |
| Genus plc | 6.4 Million USD | 1831.688% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 1237.577% |
| Pharming Group N.V. | -4.87 Million USD | -2171.278% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -5479.118% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -11799.332% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -1227.281% |
| ContraFect Corporation | -56.88 Million USD | -94.814% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -2333.253% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -7805.044% |
| IMV Inc. | -38.67 Million USD | -186.588% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -3928.88% |
| MultiCell Technologies, Inc. | -722.81 USD | -15332836.733% |
| ONE Bio Corp. | 13.68 Million USD | 910.054% |
| Accustem Sciences Inc. | -3.74 Million USD | -2858.238% |
| RVL Pharmaceuticals plc | -58.99 Million USD | -87.876% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -22842.811% |
| Q BioMed Inc. | -3.44 Million USD | -3116.493% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 3230.734% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -4117.967% |
| Biomind Labs Inc. | -1 Million USD | -10877.384% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | -101.607% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -3720.009% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -1567.084% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -5844.528% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -369918.697% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -5634.628% |
| GB Sciences, Inc. | -1.42 Million USD | -7701.992% |
| Alpha Cognition Inc. | -9.7 Million USD | -1041.897% |
| HST Global, Inc. | -140.9 Thousand USD | -78553.296% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -9752.201% |
| Halberd Corporation | -75.05 Thousand USD | -147572.219% |
| Enzolytics Inc. | -2.14 Million USD | -5057.669% |
| Agentix Corp. | -1.37 Million USD | -7979.279% |
| Resverlogix Corp. | -12.74 Million USD | -769.307% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -3398.056% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 73.926% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -10515.709% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -3696.202% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -6917.295% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -3154.881% |
| AVAX Technologies, Inc. | 6.69 Million USD | 1755.909% |
| Zenith Capital Corp. | -8.94 Million USD | -1139.271% |
| Genscript Biotech Corporation | -415.79 Million USD | 73.345% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -636074.732% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -4413.796% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -64519.146% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -5428.251% |
| Kadimastem Ltd | -3.04 Million USD | -3545.358% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -11162.402% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -60967.306% |
| LadRx Corporation | -3.82 Million USD | -2798.505% |
| Cell Source, Inc. | -4.32 Million USD | -2462.292% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -16033.343% |
| NovAccess Global Inc. | -2.46 Million USD | -4392.857% |
| Affymax, Inc. | -15.04 Million USD | -636.594% |
| Itoco Inc. | -919.14 Thousand USD | -11957.793% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -2514.846% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -9804.2% |
| Mobile Lads Corp. | -554.55 Thousand USD | -19885.213% |
| CytoDyn Inc. | -18.05 Million USD | -513.734% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -440217.839% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -50258.509% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -19525.197% |
| SYBLEU INC | -149.18 Thousand USD | -74191.46% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -6001.788% |
| International Stem Cell Corporation | -663 Thousand USD | -16616.139% |
| Bioxytran, Inc. | -3.82 Million USD | -2801.145% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -210439.514% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -544777.089% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | -205.598% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -6749.691% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -14961.529% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -3462.456% |
| Neutra Corp. | -229.48 Thousand USD | -48194.014% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -531.895% |
| PureTech Health plc | -146.19 Million USD | 24.194% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | -415.692% |
| IXICO plc | -1.43 Million USD | -7612.457% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -1067.717% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 9.013% |
| CSL Limited | 3.81 Billion USD | 102.907% |
| Cellectis S.A. | -108.85 Million USD | -1.81% |